Phase II trial of ethinylestradiol for aromatase inhibitor-resistant postmenopausal advanced/recurrent breast cancer patients
Not Applicable
- Conditions
- aromatase inhibitor-resistant advanced/recurrent breast cancer
- Registration Number
- JPRN-UMIN000015698
- Lead Sponsor
- Keio University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1. Inflammatory breast cancer 2. Any malignant neoplasms 3. Severe cardiac disease(e.g. myocardial infarction, valvular disease, heart failure) 4. Liver cirrhosis 5. Thrombosis 6. Judged inappropriate by physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response Rate; RR
- Secondary Outcome Measures
Name Time Method Clinical Benefit Rate; CBR Adverse Drug Reaction; ADR Progression-Free Survival; PFS
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does ethinylestradiol modulate estrogen receptor signaling in aromatase inhibitor-resistant postmenopausal breast cancer (JPRN-UMIN000015698)?
What is the efficacy of ethinylestradiol compared to standard-of-care therapies like fulvestrant or CDK4/6 inhibitors in aromatase inhibitor-resistant breast cancer patients (JPRN-UMIN000015698)?
Which biomarkers, such as ESR1 mutations or ER expression levels, predict response to ethinylestradiol in aromatase inhibitor-resistant postmenopausal breast cancer (JPRN-UMIN000015698)?
What are the potential adverse events associated with ethinylestradiol treatment in aromatase inhibitor-resistant breast cancer (JPRN-UMIN000015698), and how are they managed?
Are there combination therapies involving ethinylestradiol and other hormonal agents that enhance outcomes in aromatase inhibitor-resistant breast cancer (JPRN-UMIN000015698)?